%0 Journal Article
%A Cassinello, J
%A Arranz, J A
%A Piulats, J M
%A Sanchez, A
%A Perez-Valderrama, B
%A Mellado, B
%A Climent, M A
%A Olmos, D
%A Carles, J
%A Lazaro, M
%T SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
%D 2017
%U http://hdl.handle.net/10668/11795
%X Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
%K Abiraterone
%K Androgen deprivation treatment
%K Cabazitaxel
%K Castration-resistant prostate cancer
%K Docetaxel
%K Enzalutamide
%K Hormone-sensitive advanced prostate cancer
%K Radium 223
%~